The E7 protein encoded by the oncogenic human papillomavirus type 16 has been shown to bind and inactivate insulin-like growth factor-binding protein-3 (IGFBP-3), the pro-apoptotic product of a tumour suppressor gene; however, the molecular mechanism underlying E7-induced inactivation of IGFBP-3 remained uncertain. In this study, we map the IGFBP-3-binding domain for E7 to the nuclear localization signal in the conserved C-terminal domain of IGFBP-3. Moreover, we demonstrate that both proteins interact in the nucleus and that E7 induces polyubiquitination and proteasome-dependent proteolysis of nuclear IGFBP-3 in cervical cancer cells. This leads to a dramatic shortening of the half-life of nuclear IGFBP-3, whereas the stability of an E7-non-binding IGFBP-3 mutant is not affected by E7. Finally, we show that E7-mediated destruction of nuclear IGFBP-3 correlates with the inhibition of IGFBP-3-induced apoptotic cell death. These data are consistent with E7-induced ubiquitin/proteasome-dependent inactivation of nuclear IGFBP-3.
Introduction
Human papillomaviruses (HPVs) of the high-risk type are associated with cervical squamous intra-epithelial lesions with a high potential for progression to invasive cervical squamous cell carcinoma in humans (1) . HPV-16 is the most prevalent high-risk genotype. The viral E6 and E7 oncogenes are necessary for maintenance of the transformed phenotype (1) and regularly expressed in HPV-positive cancers (2) . According to current concepts of multi-step carcinogenesis, several growth-suppressing pathways must be independently subverted by E7 in order to immortalize primary human epithelial cells (3) . In accordance with this hypothesis, E7 has the ability to interact with and functionally inactivate several cellular growth regulatory proteins, as best studied for the retinoblastoma tumour suppressor protein.
Insulin-like growth factor-binding protein-3 (IGFBP-3) is a key component of the insulin-like growth factor-I (IGF-I)/IGFBP-axis of growth regulatory proteins, which plays an important role in tumorigenesis (4) . IGFBP-3 can bind IGF-I and thereby regulate the mitogenic activity of IGF-I in the extracellular environment. The IGFBP-3 gene is transcriptionally activated by the tumour suppressor p53 (5) and increased expression of IGFBP-3 contributes to both p53-dependent and -independent apoptosis (6) . IGF/IGF-receptor (IGF-R)-independent actions of IGFBP-3 contribute also to its anti-proliferative and proapoptotic activities (7) . For example, IGFBP-3 can induce programmed cell death in immortalized IGF-R-negative mouse fibroblasts (6) , and IGFBP-3 mutants that do not bind IGFs can stimulate apoptosis in prostate cancer (8) and breast cancer cells (9) . Moreover, the expression of an IGF-non-binding IGFBP-3 mutant induces apoptosis and inhibits prostate tumour progression in a transgenic mouse model of prostate cancer (10) . The mechanisms underlying IGF-independent actions of IGFBP-3 may involve regulation of gene expression via activation of cell-surface receptor kinases or directly by nuclear IGFBP-3 (4). IGFBP-3 contains a nuclear localization sequence (NLS) in its conserved C-terminal domain (11) , and importin-bdependent import from the cytosol into the nucleus has been demonstrated (12) . Moreover, after addition to the cell culture supernatants, IGFBP-3 has been detected in the nuclei of different human cancer cell types (8) and human keratinocytes (13) . The interaction of IGFBP-3 with the nuclear retinoid X receptor was found essential for mediating the effects of IGFBP-3-induced apoptosis in prostate cancer cells (14) , supporting the notion that nuclear IGFBP-3 functions in the induction of programmed cell death. Furthermore, it was shown that the abundance and pro-apoptotic activity of nuclear IGFBP-3 are regulated by ubiquitin/proteasome-dependent proteolysis (15) . However, the nuclear functions of IGFBP-3 and the mechanisms that control the activity of nuclear IGFBP-3 are still poorly understood.
It was previously demonstrated that HPV-16 E7 can inhibit IGFBP-3-mediated apoptosis (16) ; the viral oncoprotein interacts with IGFBP-3 and triggers its proteolytic cleavage. Although these findings suggest that inactivation of IGFBP-3 is important for the oncogenic activity of E7, the precise mechanism underlying E7-dependent inactivation of IGFBP-3 remained uncertain. The aim of this study was to investigate functional consequences of the E7-IGFBP-3 interaction.
Material and methods

Plasmid constructions
The plasmids pXIGFBP-3, pXIGFBP-3KED253-255RGD, pXIGFBP-3KGRKR228-232MDGEA, pXDls-IGFBP-3, pXDls-IGFBP-3KGRKR228-232MDGEA, pXDls-IGFBP-3D185-264, pCIneoHis 6 -Dls-IGFBP-3 and pCIneoHis 6 -Dls-IGFBP-3KGRKR228-232MDGEA are described (15) . The plasmids pXIGFBP-3D89-184 and pXIGFBP-3D89-264 are derived from pSF208 and pSF209 (17) . To generate pXls-IGFBP-3D1-164, an EcoRI/XhoI IGFBP-3(165-264) fragment was isolated from pJG4-5IGFBP-3 165-264 (Boris Mannhardt, Deutsches Krebsforschungszentrum, Heidelberg) and inserted into pX. The oligonucleotide 5#-aattcgatatcatgcagcgggcgcgacccacgctctgggccgctgcgctgactctgctggtgctgctccgcgggccgcggtggcgcgggctg-3# containing atg and leader sequence was inserted into the EcoRI site. pGEX-4T1, pGST-HPV-16 E7 and pXHPV-16 E7 are described (16) . The retroviral expression vector pSITVneo-HPV-16 E7 was generated by insertion of HPV-16 E7 cDNA as NotI/EcoRI fragment into pSITVneo MCS (18) . Human ubiquitin cDNA was amplified from a cDNA library using the primers 5#-aaggaaaaaagcggccgcgatgcagatctttgtgaagaccctcact-3# and 5#-cggggtaccttacccacctcgcaggcgcaacaccag-3# and inserted as NotI/KpnI fragment into p3 Â Flag-CMV-10 (Sigma-Aldrich, Vienna) generating p3 Â Flag-CMV-10-Ubiquitin.
Cell culture
Human cervical carcinoma cells C33A (HPV negative) (19) and CaSki (HPV-16 positive) (2) and U-2OS cells were cultured in Dulbecco's modified Eagle's medium/10% foetal calf serum. Cells were transfected using Effectene (Qiagen, Vienna). C33AdoxE7 was generated by the infection of C33A cells with pLIB-rtTA-M2-ires-TRSID-ires-Puro self-inactivating retrovirus vector, containing the tetracycline-transactivator/repressor sequences (18) . Cells were selected for stable transfectants by puromycin and single clones infected with the pSITVneo-HPV-16 E7 self-inactivating retrovirus vector. Stable transfectants were selected by neomycin and tested for HPV-16 E7 expression upon induction by 1 lg/ml doxycycline.
GST pull-down assays Glutathione S-transferase (GST) pull-down assays were performed as described (16) using conditioned media from U-2OS cells secreting ectopically expressed IGFBP-3s (20) .
Co-immunoprecipitation
Cells were incubated with 100 lM LLnL (Sigma, Vienna) for 3 h and co-immunoprecipitation was conducted as described (16) , using goat anti-HPV-16 E7 (21), goat anti-IGFBP-3 antibodies (15) or goat control serum.
Indirect immunofluorescence
Cells were fixed with 4% (wt/vols) paraformaldehyde/phosphate-buffered saline (PBS) and permeabilized with 0.1% (wt/vols) Na-citrate/0.3% (vol/vols) Triton-X-100. After blocking with 1% (wt/vols) bovine serum albumin/PBS, cells were incubated for 1 h with goat polyclonal anti-IGFBP-3 antibodies (DSL, Sinsheim) in blocking buffer. Cells were washed in 1% bovine serum albumin/PBS, blocked with 1% (wt/vols) bovine serum albumin/PBS and incubated for 1 h at room temperature with affinity-purified rabbit polyclonal anti-HPV-16 E7 antibodies (20 lg/ml), which were pre-incubated with 2.5 lg/ ll of the 20 000g supernatant of an NIH3T3 total-cell extract in blocking buffer for 1 h at room temperature. Cells were processed for immunofluorescence analysis as described (2) and viewed using confocal microscopy.
Subcellular fractionation
Cell fractionations were conducted using the Qproteome Cell Compartment Kit (Qiagen). IGFBP-3 and HPV-16 E7 abundance was analysed by western blotting in cytosolic, membranous and nuclear fractions produced from 5 Â 10 6 cells. Antibodies used as cell fractionation markers are as follows: a-M2PK (Schebo Biotech AG, Wettenberg), a-GM130 and a-Calnexin (BDBiosciences, Schwechat) and a-lamin B (Oncogene, Boston, MA).
Western blotting
Western blotting was performed as described (15) .
Protein half-life determination C33AdoxE7 cells were transfected with plasmids expressing Dls-IGFBP-3 or Dls-IGFBP-3KGRKR228-232MDGEA together with a b-galactosidase expression vector to monitor equal transfection efficiency and loading. E7 expression was induced with doxycycline, and IGFBP-3 half-lives were determined as described (15) .
In vivo ubiquitination assay C33A and U-2OS cells were transiently cotransfected with expression vectors for His 6 -Dls-IGFBP-3, His 6 -Dls-IGFBP-3KGRKR228-232MDGEA, HPV-16 E7, empty vector and p3 Â Flag-CMV-10-Ubiquitin as indicated. Twenty-one hours later, cells were incubated with 100 lM LLnL for 3 h and lysed in stabilizing buffer [1% (wt/vols) sodium dodecyl sulphate, 50 mM Tris-HCl, pH 6.8], sonified and denatured for 10 min at 95°C. The His-tag-IGFBP-3s were purified as described (15) , separated on a 10% sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE) and detected by western blotting using polyclonal goat anti-IGFBP-3 and monoclonal anti-Flag antibodies (Sigma).
In vitro ubiquitination assay Secreted His-tag-IGFBP-3 wild-type protein was purified from supernatants of U-2OS cells expressing IgK-His-Dls-IGFBP-3 (15) . HPV-16 E7 protein was purified as described (20) . Adenosine triphosphate-dependent ubiquitin conjugation of IGFBP-3 (þ/À HPV-16 E7) was conducted using ubiquitin: GSTubiquitin mix (4:1), ubiquitin-vinyl-sulfone and Ubiquitin Protein Conjugation Kit (BostonBiochem, Cambridge, MA). 
Statistical analysis
Student's t-test was used.
Results
HPV-16 E7 binds to the NLS in the conserved C-terminal domain of IGFBP-3 HPV-16 E7 interacts with IGFBP-3 via a domain localized within its C-terminal region (16) . To identify the E7-binding domain in IGFBP-3, we employed IGFBP-3 mutants ( Figure 1A) . Each mutation targets a distinct region of IGFBP-3, the conserved N-terminal domain, the non-conserved central and the conserved C-terminal domain (IGFBP-3D89-264, D185-264, D89-184, D1-164, KGRKR228-232MDGEA and KED253-255RGD), respectively. IGFBP-3 wild-type and the mutants were expressed in human U-2OS cells, and the secreted IGFBP-3 proteins analysed for their interaction with E7 in GST pull-down experiments. IGFBP-3 wild-type interacted strongly and in a dosedependent manner with purified GST-16 E7 but not with GST alone ( Figure 1B ). While the interaction with E7 was completely abolished in constructs lacking the C-terminal domain of IGFBP-3 (IGFBP-3D89-264 and IGFBP-3D185-264), IGFBP-3D89-184 (containing the conserved N-terminal and C-terminal regions) and IGFBP-3D1-164 (containing the conserved C-terminal domain) were able to bind E7, although with reduced efficiency compared with IGFBP-3 wildtype ( Figure 1C ). These observations indicate that E7 binds to the conserved C-terminal domain of IGFBP-3. Two additional IGFBP-3 mutants were employed to precisely map the domain of IGFBP-3 required for the interaction with E7, IGFBP-3KGRKR228-232MDGEA in which the NLS is inactivated and IGFBP-3KED253-255RGD in which three amino acids in the NLS-adjacent region are altered (KED to RGD) (17) . The binding of E7 to IGFBP-3 was completely abrogated by the mutation of the NLS, whereas the mutation of the KED motif had no effect on binding ( Figure 1D ). These findings indicate that the NLS in the C-terminus of IGFBP-3 is required for its interaction with E7.
HPV-16 E7 co-localizes with IGFBP-3 in the nucleus and induces a reduction in the nuclear IGFBP-3 steady-state levels To determine a potential nuclear interaction between both proteins, U-2OS cells were transiently transfected with pXDls-IGFBP-3 encoding a form of IGFBP-3 that localizes predominantly to the nucleus (15) . The cells were stained with a-IGFBP-3 antibodies and viewed by indirect immunofluorescence microscopy using a confocal laser scanning system. The anti-IGFBP-3 antibodies predominantly stained the nucleus of the transiently transfected cells ( These findings suggest that co-expression of E7 and IGFBP-3 in the nucleus leads to a drastic reduction of the IGFBP-3 level. When U-2OS cells were transiently cotransfected with pXDls-IGFBP-3KGRKR228-232MDGEA and pXHPV-16 E7, the IGFBP-3 staining was predominantly cytosolic and E7 staining predominantly nuclear ( Figure 2A , panels 3 and 5, bottom). The staining intensity of the Dls-IGFBP-3KGRKR228-232MDGEA protein was not significantly affected by E7 cotransfection, suggesting that the abundance of the cytosolic E7-non-binding IGFBP-3 mutant is not reduced by E7-coexpression. To support these conclusions, U-2OS cells were transiently transfected with pXDls-IGFBP-3 and increasing amounts of pXHPV-16 E7 and the impact of E7 on the nuclear IGFBP-3 levels monitored by western blotting ( Figure 2B ). This experiment was three times repeated and the IGFBP-3 bands were densitometrically analysed. E7 induced a significant reduction in the steady-state levels of nuclear IGFBP-3 ( Figure 2B , left). The steady-state levels of the predominantly cytosolic E7-non-binding mutant Dls-IGFBP-3KGRKR228-232MDGEA were not altered by co-expression of E7 ( Figure 2B , right). These findings indicate that the abundance of nuclear IGFBP-3 protein is reduced by co-expression of HPV-16 E7.
Since HPV-16 cause cervical cancer (1), we monitored the intracellular distribution of endogenous E7 and IGFBP-3 in the HPV-16-positive cervical carcinoma CaSki cells by indirect immunofluorescence experiments using confocal laser scanning microscopy. When CaSki cells were stained with the anti-HPV-16 E7 and anti-IGFBP-3 antibodies, predominantly cytoplasmic staining was found for IGFBP-3 ( Figure 2C, upper panel, green) , whereas in most of the cells, the E7 staining was nuclear and cytoplasmic ( Figure 2C, upper panel, red) .
When both signals were superimposed, we found a co-localization of E7 and IGFBP-3 on distinct areas around the nuclear envelope ( Figure 2C , upper panel, merge). When the specific 26S proteasome inhibitor epoxomicin (22) was added to CaSki cells, we observed a significant increase of the nuclear E7 signal as well as the IGFBP-3 signal in the area around the nuclear envelope/periphery ( Figure 2C , lower panels); moreover, co-localization of both proteins was more pronounced in this area ( Figure 2C , lower panels). The pre-immunesera did recognize neither IGFBP-3 nor E7 in CaSki cells (2,15 and data not shown). These results suggest that endogenous epoxomicin-stabilized IGFBP-3 and E7 co-localize near the nuclear envelope or in the nuclear periphery in CaSki cells and that E7 induces a reduction of the IGFBP-3 protein levels at these sites.
HPV-16 E7-induced reduction of nuclear IGFBP-3 protein level requires a functional proteasome Since nuclear IGFBP-3 is a target for ubiquitin/proteasome-dependent destruction in U-2OS cells (15), we wondered whether the E7-induced reduction in nuclear IGFBP-3 protein level is caused by proteasomedependent proteolysis in cervical cancer cells. To investigate this, we performed a fractionation experiment analysing endogenous IGFBP-3 wild-type and E7 protein levels in subcellular fractions of epoxomicin A GST pulldown experiment was performed with purified GST and GST-HPV-16 E7 proteins incubated with increasing amounts of IGFBP-3 wild-type protein. After washing, bound proteins were separated by SDS-PAGE, transferred to a polyvinylidene difluoride membrane and probed with antibodies against IGFBP-3 and GST (Input 5 100 ll conditioned medium). (C and D) E7 binds to the NLS in the conserved C-terminal domain of IGFBP-3. GST pull-down experiments were performed with purified GST and GST-HPV-16 E7 proteins incubated with various IGFBP-3 deletion (C) and point mutants (D), as indicated. After washing, bound proteins were separated by SDS-PAGE, transferred to a polyvinylidene difluoride membrane and probed with antibodies against IGFBP-3 and GST.
Inhibition of apoptosis by human papillomavirus type 16 E7 oncoprotein and mock-treated CaSki cells. We prepared nuclear, cytosolic and membranous fractions and analysed the level of endogenous IGFBP-3 and E7 proteins by western blotting ( Figure 3A) . As expected, the nuclear protein lamin B was retrieved in the nuclear fraction, whereas the cytosolic marker pyruvate kinase (M2-PK) was exclusively detected in the cytosol fraction, and the Golgi marker GM130 and the endoplasmic reticulum-specific protein calnexin were found exclusively in the membrane fraction, suggesting that a clean separation of proteins from the nuclear, cytosolic and membranous fractions had been achieved. In the mock-treated CaSki cells, the majority of the endogenous IGFBP-3 wild-type protein was detected in the membrane fraction but a significant amount was also localized in the nuclear fraction, indicating that endogenous IGFBP-3 exists in the nucleus as well as in the cytoplasm of CaSki cells. E7, which is well described as a nuclear and cytoplasmic protein (2, 3, 23) , was detectable in cytoplasmic as well as nuclear CaSki cell fractions (Figure 3A) , as shown before (24) . Though E7 is predominantly localized in nuclei ( Figure 2C ), little E7 protein could be fractionated in the nuclear fraction ( Figure 3A ). This can be explained by leakage, which can happen especially for small molecules like the 11 kda E7 protein.
Thus, these findings underline that significant amounts of both IGFBP-3 and E7 protein are co-localized in the nucleus as shown in Figure 2 . Epoxomicin treatment led to a significant increase of the endogenous IGFBP-3 wild-type protein level in the total-cell extract of CaSki cells indicating that epoxomicin stabilizes endogenous IGFBP-3 in the presence of E7 in cervical cancer cells ( Figure 3A) . E7, a well-known target of proteasome-dependent destruction (3), was stabilized under these conditions in all cell fractions and could be detected together with increased IGFBP-3 level in the membrane and nuclear fractions.
To present additional evidence that nuclear IGFBP-3 is stabilized by epoxomicin in E7-expressing cervical cancer cells, epoxomicin was added to C33A cells transiently transfected with pXDls-IGFBP-3 and/or pXHPV-16 E7. Nuclear localization of both proteins was controlled by indirect immunofluorescence analysis ( Figure 3B ). Both proteins were expressed in the nucleus and co-expression of E7 and IGFBP-3 led to reduced nuclear IGFBP-3 level in C33A cells. Lysates from these cells were separated on a SDS-PAGE and the IGFBP-3 protein level analysed by western blotting using anti-IGFBP-3 antibodies ( Figure 3C ). In this experiment, E7 induced a strong reduction in the steady-state levels of Dls-IGFBP-3 ( Figure  3C, compare lanes 1 and 3) . The abundance of Dls-IGFBP-3 was not reduced by E7 in epoxomicin-treated cells, although epoxomicin treatment led to increased E7 protein levels, indicating that E7-induced degradation of IGFBP-3 occurs via proteasome-dependent proteolysis ( Figure 3C, compare lane 4 with lanes 1-3) . The steadystate levels of the E7-non-binding mutant Dls-IGFBP-3KGRKR228-232MDGEA, which is predominantly localized in the cytosol of C33A cells ( Figure 3B ), were not significantly altered by E7 ( Figure 3C , compare lanes 5 and 6), thus linking the reduction of the IGFBP-3 steady-state levels in the nucleus with its binding to E7. Together, these experiments indicate that E7 induces proteasome-dependent destruction of nuclear IGFBP-3.
E7-dependent reduction of nuclear IGFBP-3 is caused by decreased protein stability To analyse the mechanism underlying E7-induced reduction of Dls-IGFBP-3, the half-life of Dls-IGFBP-3 was determined in the presence and absence of E7 (Figure 4) . To do this, C33AdoxE7 cells were employed in which E7 is expressed under the control of a doxycycline-inducible promoter. E7 was well expressed 15 h after induction with doxycycline but not detectable without doxycycline ( Figure 4A ), indicating that E7 expression is tightly regulated. To determine the influence of E7 on the half-life of nuclear IGFBP-3, C33AdoxE7 cells were transiently transfected with pXDls-IGFBP-3 and E7 expression was induced. Cycloheximide was added to block cellular protein synthesis, ruling out any influence of altered protein synthesis on the IGFBP-3 steady-state levels and metabolic half-life. Cells were lysed in sodium dodecyl sulphate sample buffer following a time course and the IGFBP-3 levels analysed by SDS-PAGE and western blotting using polyclonal anti-IGFBP-3 antibodies ( Figure 4B, upper panel) . The intensity of the IGFBP-3 bands was measured densitometrically and the half-life (T 1/2 ) calculated by half-logarithmic plotting of the intensity of the bands against the cycloheximide incubation time ( Figure 4B, lower panel) . The half-life of Dls-IGFBP-3 was 94.1 ± 20.3 ( x ± SD, n 5 4) min in the absence of E7 and 37.3 ± 3.3 ( x ± SD, n 5 4) (P 5 0.0007, þE7 versus ÀE7) min in the presence of E7. The same assay performed with predominantly cytosolic non-E7-binding IGFBP-3 (Dls-IGFBP-3KGRKR228-232MDGEA) showed a half-life of 70.0 ± 36.9 ( x ± SD, n 5 3) min without E7 and 91.2 ± 30.3 ( x ± SD, n 5 4) (not significant, þE7 versus ÀE7) min with E7 ( Figure 4C , lower panel). In conclusion, these findings demonstrate that E7 efficiently induces the proteolysis of Dls-IGFBP-3.
Identifying Dls-IGFBP-3 as E7 target, we aimed to strengthen this finding by the demonstration that both proteins interact in a cellular context using a co-immunoprecipitation assay. To do this, U-2OS cells, which display an intrinsic high transfection efficiency, were transiently cotransfected with pXHPV-16 E7 and/or pXDls-IGFBP-3 as indicated ( Figure 4D ), and the 26S proteasome inhibitor LLnL was added 3 h before cell lysis. Goat anti-IGFBP-3 antibodies specifically co-precipitated E7 with IGFBP-3 from extracts of cells overexpressing E7 and Dls-IGFBP-3 ( Figure 4D ), and goat anti-E7 antibodies specifically co-precipitated Dls-IGFBP-3 with E7 from extracts of cells co-expressing E7 and nuclear IGFBP-3, whereas immunoprecipitation of IGFBP-3 was not achieved from the control cells ( Figure 4D ). Moreover, goat pre-immuneserum did precipitate neither IGFBP-3 nor E7 in extracts from IGFBP-3-and E7-expressing cells ( Figure 4D ). These data suggest that E7 can form a specific complex with Dls-IGFBP-3 in a cellular context.
HPV-16 E7 enhances polyubiquitination of nuclear IGFBP-3
Subsequently, an in vivo ubiquitination assay was performed to test whether E7 triggers IGFBP-3 proteolysis by the ubiquitin/proteasome pathway ( Figure 5A ). U-2OS cells were transiently cotransfected with expression vectors for nuclear His-tag-IGFBP-3 and 3 Â Flag-tagubiquitin and lysates prepared 24 h later. His-tag-Dls-IGFBP-3 derivatives were purified, normalized for the presence of identical amounts of IGFBP-3 by western blotting, using anti-IGFBP-3 polyclonal sera ( Figure 5A , lower panels), and analysed for polyubiquitination by western blotting using anti-Flag antibodies ( Figure 5A, lane 1, upper  panel) . Under these conditions, polyubiquitinated IGFBP-3 conjugates could be detected. When E7 was transiently co-expressed ( Figure 5A , lane 2), a significant increase of the amount of polyubiquitinated IGFBP-3 was detected ( Figure 5A, lane 2, upper panel) . Similar experiments were performed in C33A cervical cancer cells. Again, the level of polyubiquitinated Dls-IGFBP-3 was higher with E7 Figure 5A, lane 4) . E7 did not affect the polyubiquitination levels of the E7-non-binding mutant Dls-IGFBP-3KGRKR228-232MDGEA ( Figure 5A , compare lanes 6 and 7). The comparison of the level of polyubiquitinated IGFBP-3 between E7-expressing (115.1 ± 7.5%, x ± SD, n 5 4) and nonexpressing (100%, x ± SD, n 5 4) cells showed a significant E7-induced increase in IGFBP-3 polyubiquitination (P 5 0.003). To corroborate these findings, we analysed the impact of E7 on IGFBP-3 polyubiquitination using a cell-free reconstituted rabbit reticulocyte lysate-based ubiquitination system ( Figure 5B ). IGFBP-3 per se was polyubiquitinated in this in vitro assay and an increase in the polyubiquitination level of IGFBP-3 was achieved after adding E7 to the reaction. Together, these results indicate that E7 specifically enhances polyubiquitination of IGFBP-3.
HPV-16 E7 inhibits apoptotic cell death induced by nuclear IGFBP-3 in C33A cells Transient transfection of C33A cells with an expression vector for IGFBP-3 wild-type induced a significant increase in the percentage of annexin-V-positive cells relative to mock-transfected cells (Figure 6 ), suggesting that transiently expressed IGFBP-3 wild-type induces apoptosis in these cells. Co-expression of E7 with IGFBP-3 led to a significant reduction in the amount of apoptotic C33A cells, indicating that E7 can abrogate IGFBP-3 wild-type-induced apoptosis in C33A cells, as shown previously in PC3 cells (16) . When Dls-IGFBP-3 was transiently expressed in C33A cells under the same conditions, we found a significant increase in the percentage of cells undergoing apoptosis, suggesting that predominantly nuclear IGFBP-3 can readily induce apoptosis in the C33A cells. Co-expression of E7 resulted in a significant abrogation of the pro-apoptotic activity of Dls-IGFBP-3 ( Figure 6 ). Moreover, we found that transient expression of the predominantly cytosolic E7-non-binding mutant Dls-IGFBP-3KGRKR228-232MDGEA led also to a significant increase in the percentage of apoptotic cells ( Figure 6) ; however, co-expression of E7 resulted not in a significant abrogation of the pro-apoptotic activity of this IGFBP-3 mutant (Figure 6 ). Together, these findings suggest that E7 specifically prevents apoptosis mediated by nuclear IGFBP-3.
Discussion
In this study, we demonstrate for the first time that the HPV-16 E7 oncoprotein regulates the abundance of nuclear IGFBP-3 by inducing its polyubiquitination and proteasome-dependent degradation in cervical cancer cells. This contributes to the inhibition of apoptotic cell death induced by nuclear IGFBP-3, suggesting that the accumulation of nuclear IGFBP-3 is not compatible with cervical cancer cell survival. These results contribute to a better understanding of the role of ubiquitin/proteasome-dependent proteolysis for the oncogenic activity of E7, and are consistent with the model that E7 needs to inactivate several tumour suppressor pathways important to the oncogenic potential of the virus (3).
A nuclear interaction with HPV-16 E7 triggers polyubiquitination and degradation of IGFBP-3
The ability to interact with E7 is severely impaired by a point mutation in the NLS localized in the conserved C-terminal domain of IGFBP-3. Since none of the deletion mutants employed in this study had the capability to bind E7 with high affinity, the intact structure of IGFBP-3, including both N-terminal and C-terminal domains, may be required for efficient E7 binding, as was shown for high-affinity binding of IGFBP-3 to IGF-I (25). IGFBP-3 has been shown to bind via its NLS to importin b, and nuclear import of IGFBP-3 is mediated in a Ran-dependent process by the a and b importin subunits, which constitute the high-affinity NLS receptor used by many proteins to affect their nuclear import (26) . Whereas the abundance of nuclear IGFBP-3 is regulated by ubiquitin/proteasome-dependent degradation (15) , the molecular mechanisms underlying its proteasome-mediated destabilization are not yet well understood. Proteasomes are abundantly found in both nuclei and the cytosol of eukaryotic cells but Fig. 3 . HPV-16 E7-induced reduction of nuclear IGFBP-3 protein level in CaSki and C33A cells requires a functional proteasome. (A) CaSki cells were incubated for 3 h with either 10 lM epoxomicin or dimethyl sulfoxide as indicated, and subjected to lysis and cell fractionation. The endogenous IGFBP-3 and HPV-16 E7 levels were analysed in total cell lysates, cytosolic, membranous and nuclear fractions separated by SDS-PAGE in western blotting experiments using antibodies against HPV-16 E7 and IGFBP-3. Correct cell fractionation was asserted using antibodies against lamin B (nucleus), calnexin (endoplasmic reticulum), GM130 (Golgi) and pyruvate kinase (M2-PK) (cytosol). (B) Co-localization of HPV-16 E7 and Dls-IGFBP-3 in C33A cells. C33A cells were transiently cotransfected with empty vector and expression vectors for predominantly nuclear IGFBP-3 (pXDls-IGFBP-3), predominantly cytosolic IGFBP-3 (pXDls-IGFBP-3KGRKR228-232MDGEA) and pXHPV-16 E7 as indicated and analysed by indirect immunofluorescence microscopy. Cells were stained with antibodies against IGFBP-3 (green) and HPV-16 E7 (red) or the signals were merged (yellow). (C) HPV-negative C33A cells were transiently transfected with expression plasmids for predominantly nuclear IGFBP-3 (pXDls-IGFBP-3) or predominantly cytosolic IGFBP-3 (pXDls-IGFBP-3KGRKR228-232MDGEA) and HPV-16 E7 (lane 3, 4, 6) or empty vector (lane 1, 2, 5), as indicated. b-Galactosidase was cotransfected to monitor equal transfection efficiency and loading. Cells were incubated with either 10 lM epoxomicin or dimethyl sulfoxide for 3 h and harvested in sodium dodecyl sulphateLaemmli sample buffer. Samples were separated by SDS-PAGE and a western blot was performed using antibodies against b-galactosidase, IGFBP-3 and HPV-16 E7.
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virtually absent from the lumen of membranous organelles such as the endoplasmic reticulum (27) , and this raises the question how IGFBP-3 can be degraded in a proteasome-dependent fashion. A possible solution to this paradox comes from the observations that extracellular IGFBP-3 can be internalized by cells (28) , and this is correlated with nuclear localization of IGFBP-3. Another possibility is that IGFBP-3 reaches the nucleus from its synthesis spots via an intracrine pathway as proposed for actions of non-secreted IGFBP-5 (29); however, there is currently no evidence for such a pathway for IGFBP-3. Our results indicate that endogenous E7 and IGFBP-3 co-localize near the nuclear envelope and/or in the nuclear periphery in CaSki cells. E7 binds to the NLS of IGFBP-3 in vitro and induces ubiquitin/proteasomedependent destruction of nuclear Dls-IGFBP-3 in C33A cells. Accordingly, E7 induces a dramatic reduction in the half-life of nuclear Dls-IGFBP-3 in C33A cells and this can be specifically inhibited by the proteasome inhibitor epoxomicin, whereas the metabolic half-life of the predominantly cytosolic E7-non-binding mutant Dls-IGFBP-3KGRKR228-232MDGEA is not altered in this assay. Our demonstration that E7 significantly enhances polyubiquitination of nuclear Dls-IGFBP-3, whereas polyubiquitination of the E7-non-binding mutant Dls-IGFBP-3KGRKR228-232MDGEA is not altered by E7, establishes nuclear Dls-IGFBP-3 as a target for E7-induced ubiquitin/ proteasome-dependent destruction. Consistent with the low endogenous nuclear IGFBP-3 levels in the HPV-16-positive CaSki cells, E7 is expressed in the nucleus of these cells. Both endogenous proteins E7 as well as IGFBP-3 co-localize in nuclear fractions derived from CaSki cells and the nuclear fraction of endogenous IGFBP-3 accumulates with epoxomicin treatment ( Figure 3A) . Moreover, IGFBP-3 can be stabilized by epoxomicin in areas around the nuclear envelope/ periphery of CaSki cells ( Figure 2C ). These findings suggest that endogenous E7 can induce proteasome-dependent destruction of endogenous nuclear IGFBP-3 in the nuclear periphery of CaSki cells. In keeping with these results, endogenous nuclear IGFBP-3 is only detectable in very low levels in the vast majority of tumour cells analysed so far (4) . It should be noted that the present study rules not out that E7 may also enhance degradation of cytoplasmic IGFBP-3. It is , each together with a plasmid-expressing b-galactosidase to monitor equal transfection efficiency and loading. HPV-16 E7 expression was induced with doxycycline (þDox) or not (ÀDox) for 15 h and monitored by western blotting in each fraction. The protein biosynthesis was blocked by an addition of 100 lg/ml cycloheximide and cells were harvested at the indicated time intervals in 1.5 Â sodium dodecyl sulphate-Laemmli-sample buffer. The IGFBP-3 expression levels were determined by western blotting using polyclonal goat anti-IGFBP-3 antibodies. The blot was developed using a chemiluminescence system, IGFBP-3 bands were scanned from low exposures and densitometrically analysed. The halflife of the IGFBP-3 variants was calculated by half-logarithmic plotting of the intensity of the densitometrically analysed bands against the incubation time using a logarithmic regression line. (D) HPV-16 E7 and IGFBP-3 interact in cellular lysates. U-2OS cells were transiently transfected with HPV-16 E7 and IGFBP-3 expression vectors, as indicated. Co-immunoprecipitations were performed from the lysates with either goat anti-IGFBP-3 or goat anti-HPV-16 E7 antibodies or goat preimmuneserum (IP:IgG), as indicated. The precipitated proteins were analysed by western blotting with a-IGFBP-3 or a-HPV-16 E7 antibodies. Ten percent of total cellular lysate was loaded as input control.
Inhibition of apoptosis by human papillomavirus type 16 E7 oncoprotein possible that at least a part of nuclear IGFBP-3 is reduced by its enhanced degradation in the cytoplasm by E7, as the endogenous IGFBP-3 levels are also increased in the membrane fraction of epoxomicin-treated CaSki cells ( Figure 3A) . Moreover, since E7 can not bind to the predominantly cytoplasmic mutant Dls-IGFBP-3KGRKR228-232MDGEA, more work is necessary to address the question whether E7 can also induce the degradation of cytoplasmic IGFBP-3.
A role of the proteasome in E7-induced degradation of the retinoblastoma protein (pRb), another important nuclear E7 target protein (3), is well established. E7 targets pRb to proteasome-dependent degradation, which impairs pRb-dependent growth arrest in the G 1 phase of the cell cycle (30) . Moreover, it was shown that the abundance of pRb is inversely correlated with E7 oncoprotein expression in highgrade cervical lesions, whereas pRb nearly completely disappeared in invasive cervical carcinomas in situ (2), underlining the importance of E7-mediated degradation of pRb in cervical carcinogenesis. Although the underlying mechanism is still little understood, it has been shown that E7 can interact with the S4 adenosine triphosphatase subunit of the 19S regulatory complex of the 26S proteasome which may circumvent the need for polyubiquitination (31) . More recently, it was shown that E7 can also induce polyubiquitination and proteolysis of pRb through the ubiquitin/proteasome pathway (32) . These findings suggest that E7-induced proteasome-dependent proteolysis of pRb probably involves more than one pathway, and the role of these pathways for the degradation of IGFBP-3 warrants further study.
Abrogation of IGFBP-3 induced apoptosis by HPV-16 E7
Expression of the IGFBP-3 gene is induced by the tumour suppressor proteins p53 (5) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) (33) , as well as by several pro-apoptotic and growth inhibitory factors, like transforming growth factor-ß (6) and retinoic acid (34) , suggesting that IGFBP-3 itself might act as a tumour suppressor, presumably via its ability to halt proliferation and induce apoptosis in cancer cells. IGFBP-3 can induce apoptotic cell death by several pathways (reviewed in refs 4 and 7). It can modulate the anti-apoptotic effects of IGF-I by regulating the IGF-I-IGF-R-I interaction (reviewed in refs 4 and 7). Moreover, induction of programmed cell death through IGF-R-I-independent mechanism (6, 8, 9, 35, 36) and by exclusively intracellular cytoplasmic (15, 37) as well as nuclear IGFBP-3 (14,15) has been demonstrated (reviewed 7) were transiently cotransfected with expression vectors for 3 Â Flag-Ubiquitin, His 6 -Dls-IGFBP-3, His 6 -Dls-IGFBP-3KGRKR228-232MDGEA, HPV-16 E7 and empty vector, as indicated. Twentyfour hours after transfection, the cells were lysed in a stabilizing buffer. His-tagged IGFBP-3 variants were purified from the lysates by nickel-chelate affinity chromatography. The eluates were separated on a SDS-PAGE, and western blot analysis with polyclonal goat anti-IGFBP-3 antibodies and monoclonal anti-Flag antibodies was performed. Note, the last 3 h before harvesting the cells were cultured in the presence of LLnL. (B) IGFBP-3 wild-type protein (1 lg) purified from U-2OS supernatants was subjected to in vitro ubiquitination reaction including Ubiquitin Protein Conjugation Kit (Cat# K-960, BostonBiochem), 150 lM Ubiquitin and 50 lM GST Ubiquitin (Cat# U-540, BostonBiochem), ubiquitin-vinyl-sulfone (Cat# U-202, BostonBiochem) and HPV-16 E7 (1 lg) as indicated. IGFBP-3 conjugates were separated on a 12.5% SDS-PAGE and detected by western blotting using polyclonal goat anti-IGFBP-3 and monoclonal anti-GST antibodies. Fig. 6 . HPV-16 E7 inhibits apoptotic cell death induced by nuclear IGFBP-3 in C33A cervical cancer cells. C33A cells were transiently transfected with expression vectors for IGFBP-3, IGFBP-3 mutants and HPV-16 E7 as indicated. Enhanced green fluorescent protein C1 was cotransfected and used as transfection marker. After transfection, the cells were cultured for 48 h in a medium containing 10% foetal calf serum and the percentage of apoptotic cells was measured using an annexin-V-binding assay (P values, x ± SD: Ã P , 0.05, ÃÃ P , 0.01, ÃÃÃ P , 0.001; ns, not significant).
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in refs 4 and 7) . The results of this study, that secreted IGFBP-3 wild-type and nuclear as well as cytosolic IGFBP-3 mutants can induce apoptotic cell death in C33A cervical cancer cells, are in keeping with these earlier findings. Co-expression of E7 leads to abrogation of apoptosis induced by nuclear IGFBP-3; however, apoptotic cell death induced by a predominant cytosolic E7-non-binding mutant of IGFBP-3 is not blocked by E7 in C33A cells. These results suggest that the ability of E7 to block IGFBP-3-induced apoptosis in cervical cancer cells involves direct binding and inactivation of IGFBP-3 by E7. Consistent with the previous studies, showing that the IGFBP-3 protein levels and metabolic stability are reduced in E7-immortalized keratinocytes (16) and in HPV-16-positive tumorigenic cell lines (38) , the present data suggest that immortalization of human cells by HPV-16 may involve the inhibition of the pro-apoptotic activity of nuclear IGFBP-3. This finding is in keeping with the earlier studies demonstrating that the expression of E7 suppresses apoptosis in several cell types (39) , including human prostate cancer cells (16) , normal human fibroblasts (40) and human keratinocytes (41) . However, many other studies showed that E7 can also induce a strong apoptotic response in several experimental systems (39) , indicating that the regulation of apoptosis by E7 is complex and may involve more than one regulatory pathway. Together, the results reported in the present study suggest that destruction and thereby functional inactivation of nuclear IGFBP-3 contribute to the suppression of apoptosis by E7. 
